Blog
RSS FeedPosted by Michael Wonder on 30 Aug 2021
FDA orphan drug approval: Octapharma’s Octagam 10% receives 7 years of market exclusivity for adult dermatomyositis
30 August 2021 - Octagam 10% expected to become the first treatment option for adults with rare immune-mediated inflammatory disease. ...
Posted by Michael Wonder on 27 Jul 2021
J&J and Pfizer quietly resolve Remicade biosimilar lawsuit
27 July 2021 - In 2017, Pfizer filed a lawsuit against J&J alleging that the company undertook anticompetitive practices in a ...
Posted by Michael Wonder on 07 Jun 2021
After repeated losses in the U.S., Catalyst wins a victory in Canada over a rare disease drug
3 June 2021 - In an unexpected move, Canada’s Federal Court quashed the approval of a rare disease drug after ...
Posted by Michael Wonder on 31 May 2021
Suspend intellectual property rights for COVID-19 vaccines
28 May 2021 - Waivers are essential for global vaccine equity ...
Posted by Michael Wonder on 14 May 2021
Vaccine patent waivers deserve a warning label
13 May 2021 - The move to suspend patents on COVID-19 vaccines opens up a major risk to the way the ...
Posted by Michael Wonder on 11 May 2021
International IP protection at risk for COVID-19 vaccines
11 May 2021 - The global biotech industry is united in its drive for equitable access to COVID-19 vaccines, but ...
Posted by Michael Wonder on 10 May 2021
America wants to waive patent protection for vaccines
8 May 2021 - But it will not have an immediate effect on supplies. ...
Posted by Michael Wonder on 09 May 2021
US wary of boosting China biotech with COVID vaccine patent waiver
9 May 2021 - The Biden administration is examining ways to ensure that a waiver of COVID-19 vaccine patents to ...
Posted by Michael Wonder on 06 May 2021
Medicines Australia updated position on intellectual property (in light of TRIPS waiver)
6 May 2021 - Medicines Australia continues to express our sympathies to all those affected by the pandemic. The importance ...
Posted by Michael Wonder on 06 May 2021
Australia has backed a global push to fast-track generic COVID-19 jabs
6 May 2021 - The Morrison government has joined an international push to fast-track the production of generic COVID-19 jabs, ...
Posted by Michael Wonder on 29 Oct 2020
European Patent Office rules in favour of Sanofi and Regeneron concerning Praluent (alirocumab)
29 October 2020 - Ruling invalidates Amgen’s European patent claims directed to PCSK9 antibodies relevant to Praluent (alirocumab). ...
Posted by Michael Wonder on 11 Oct 2020
Moderna vows to not enforce COVID-19 vaccine patents during pandemic
8 October 2020 - The company is also willing to license the technology behind its experimental coronavirus vaccine. ...
Posted by Michael Wonder on 08 Oct 2020
AstraZeneca vaccine document shows limit of no-profit pledge
8 October 2020 - Company has right under contract to declare pandemic over by July 2021. ...
Posted by Michael Wonder on 29 Jul 2020
Moderna’s mysterious coronavirus vaccine delivery system
29 July 2020 - For a decade, Moderna has been working to develop mRNA technology that could turn the body’s cells ...
Posted by Michael Wonder on 21 Apr 2020
Coronavirus puts big pharma’s IP regime to the test
21 April 2020 - “Chaotic” is how Jorge Contreras, a law professor at the University of Utah, describes a struggle ...